ClinicalTrials.gg
RecruitingNCT07448740Post-TEHITIUpdated Mar 4, 2026

Post-failure Stepwise Heat-Denaturated Protein Introduction for Tolerance Induction in Cow's Milk Allergy Observational Cohort Study

An observational study in Cow's Milk Protein Allergy, sponsored by Universitaire Ziekenhuizen KU Leuven. Recruiting at 5 sites in Belgium. Open to participants aged 1 Year to 18 Years. Per ClinicalTrials.gov, last updated 2026-03-04.

Sponsored by Universitaire Ziekenhuizen KU Leuven · Observational

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 7 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
30
Ages
1 Year to 18 Years
Sex
All
01

Study summary

Subjects who failed to become tolerant within 12 months after randomization within one of the three arms in the TEHITI study, can participate in the post-TEHITI observational trial to study the natural tolerance induction process.

Read the detailed description

In this observational study the investigators will study the time to complete tolerance in cow's milk allergic children who tolerate 20' heated milk but failed the OFC with unheated milk 12 months after passing the 20' boiled cow's milk OFC. Moreoever, the investigators want to document all clinical reactions and potential cofactors during the tolerance induction process. The investigators anticipate that the whole cohort will become tolerant in a time span shorter than 48 months. Therefore the study period in each participant will be 48 months or the period to achieve complete tolerance (which comes first).

02

Conditions studied

  • Cow's Milk Protein Allergy

Browse trials for

03

In context

Milk Hypersensitivity

147 studies on the registry are indexed under Milk Hypersensitivity; 26 are open to participants now.

This study's planned enrollment of 30 is below the median of 102 across 45 observational studies indexed under Milk Hypersensitivity.

Browse Milk Hypersensitivity studies →

Lead sponsor

Universitaire Ziekenhuizen KU Leuven is the lead sponsor of 963 studies on the registry; 267 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Year to 18 Years
Sexes eligible
All
Sampling method
Probability sample

Study population

Children participating in study s68299 who fail the challenge test with unheated cow's milk 12 months after initiation of the TEHITI trial, can be enrolled in this post-TEHITI study. Upon IC (and assent if appropriate) parents (and children) can participate in the current post-TEHITI observational trial. Upon enrollment in the post-TEHITI trial, specific data will be pseudonymised and collected during the clinical follow-up visits:

  • Intake of cow's milk containing food products: amount, recipe, frequency of intake in the period between two follow-up consultations
  • Clinical reactions: description and recording of potential cofactors for their presentation
  • Medication use to treat the clinical reaction
  • Relation to cow's milk intake: certain/doubtful/absent
  • Specific IgE to cow's milk proteins in peripheral blood
  • Total IgE levels in peripheral blood Individual pseudonymisation will be done by similar code as given in TEHITI trial.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants eligible for inclusion in this study must meet all of the following criteria:

  • participation in s68299
  • failure to challenge test with unheated cow's milk
  • passed challenge test with unheated cow's milk but with symptoms developing between challenge and termination visit related to cow's milk intake at home

Exclusion criteria

Exclusion Criteria:

Participants eligible for this study must not meet any of the following criteria:

  • Subjects not priorly enrolled in s68299
  • Subjects enrolled in s68299 who passed the challenge test and have no complaints upon regular cow's milk consumption at termination visit
  • Subjects who refuse to consent/assent with the study
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
30 participants (estimated)
Target follow-up
48 Months
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. Number of participants that acquire tolerance for cow's milk after initially failing a cow's milk provocation test

    The number of participants that spontaneously acquire tolerance for cow's milk after initially failing a cow's milk provocation test will be counted.

    Time frame: 48 months

Secondary outcomes

  1. Adverse clinical reactions to cow's milk protein intake during observational period

    Nature and condition of clinical reactions in relation to different heated and/or unheated forms of cow's milk protein intake during observational period

    Time frame: 48 months

07

Study locations

5 of 5 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2025 (actual). Primary completion is estimated for Oct 2030, 66 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 29, 2024
First posted
Mar 4, 2026
StartActual
Mar 31, 2025
Primary completionEst.
Oct 24, 2030
CompletionEst.
Oct 24, 2030
Last update
Mar 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07448740
Collaborators
Jessa Hospital, Imelda Hospital, Bonheiden, Algemeen Ziekenhuis Maria Middelares, AZ Sint-Jan AV
Responsible party
Dominque Bullens (Dominique MA Bullens, MD PhD, Universitaire Ziekenhuizen KU Leuven) — Principal investigator
First posted
Mar 4, 2026
Start date
Mar 31, 2025
Primary completion
Oct 24, 2030 (estimated)
Completion
Oct 24, 2030 (estimated)
Last update
Mar 4, 2026

Study contacts

Dominique MA Bullens, Prof, MD
Contact
dominique.bullens@uzleuven.be
+32016343801
Marleen Jannis
Contact
marleen.jannis@uzleuven.be
+32016343801
Jasmine Leus, MD
principal investigator · Maria Middelares Hospital, Gent
Katrien Coppens, MD
principal investigator · Imelda Hospital, Bonheiden
Sophie Verelst, MD
principal investigator · Jessa Hospital, Hasselt and KU Leuven
Kate Sauer, MD
principal investigator · AZ Sint-Jan AV

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion